Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

HCV Infection Clinical Trial

Official title:

A Phase 2, Randomized, Open-Label Trial of GS-9256 Plus GS-9190 Alone and in Combination With Ribavirin for 28 Days in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0112)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01072695
• Other study ID #: GS-US-196-0112
• Status: Completed
• Phase: Phase 2
• First received: February 19, 2010
• Last updated: May 30, 2012
• Start date: February 2010
• Est. completion date: January 2012

Study information

• Verified date: May 2012
• Source: Gilead Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Belgium: Federal Agency for Medicinal Products and Health ProductsUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

This a phase 2, randomized, open-label trial of GS-9256 plus GS-9190, two oral anti HCV drugs, for 28 days with and without ribavirin (RIBA) and with pegylated interferon (PEG)/RIBA in adults with chronic Hepatitis C virus (HCV). In Part A, approximately thirty (30) subjects 18-70 years of age who meet study entry criteria will be randomized (in other words, selected at random, like flipping a coin) to one of the two treatment groups (GS-9256 plus GS-9190 or GS-9256 plus GS-9190 plus RIBA). In Part B, an additional fifteen (15) subjects will receive 75 mg GS-9256 BID plus 40 mg GS-9190 BID in combination with PEG/RIBA. After the 28-day treatment period, subjects will receive PEG/RIBA as standard of care (SOC).

Following randomization, subjects will return for a Baseline (Day 1) visit, at which time study medication will be dispensed and subjects will enter a 28 day treatment phase. During the treatment phase, subjects will receive oral study drugs twice daily for 28 days and PEG once weekly for Part B. Subjects then receive PEG/RIBA as local SOC starting on Day 28 (not provided as part of the study). Following completion of the 28-day treatment phase, subjects will be followed for approximately 72 weeks.

Description:

GS-9256 (an HCV NS3 protease inhibitor) plus GS-9190 (non-nucleoside HCV NS5B inhibitor) will be administered for 28 days with and without RIBA (weight-based dosing) and with PEG/RIBA in treatment-naïve subjects with chronic genotype 1 HCV infection. In Part A, thirty (30) subjects with genotype 1 will be randomized to 75 mg GS-9256 BID plus 40 mg GS-9190 BID or 75 mg GS-9256 BID plus 40 mg GS-9190 BID plus RIBA 1000-1200 mg/day for 28 days. In Part B, an additional fifteen (15) subjects with genotype 1 will receive 75 mg GS-9256 BID plus 40 mg GS-9190 BID in combination with PEG/RIBA for 28 days. After the 28-day treatment period, subjects will receive PEG/RIBA as standard of care (SOC).

In Part A, for any subjects meeting pre-defined, individual, virologic criteria, PEG/RIBA standard of care will be started prior to Day 28.

Both PEG and RIBA will be administered at their currently approved dosages for treatment of HCV infection in accordance with appropriate labeling. Subjects will be monitored for safety (including ECG monitoring), antiviral activity, pharmacokinetics, and resistance 2-3 times weekly through Day 28.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: January 2012
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Adult subjects, ages 18-70

• Willing able to provide informed consent

• BMI between 18 and 36 kg/m2 (inclusive)

• Chronic HCV infection, genotype 1

• HCV RNA >/= 3 log, but < 7.2 log10 IU/ml at screen

• Liver biopsy, FibroTest, or FibroScan indicating absence of cirrhosis

• HCV treatment naïve with imminent plans to start treatment with PEG/RIBA

• QTcF </= 450 msec at screen

• ALT, AST, GGT < 5 X ULN at the screening visit

• Creatinine clearance >= 50 mL/min

• Absolute neutrophil count >= 1500/mm3

• Hemoglobin >/= 12 g/dL (female), >/= 13 g/dL (male)

• Males agree to use of effective contraception and refrain from sperm donation

• Able to comply with dosing instructions and study visits

• Of generally good health

Exclusion Criteria:

• Females of child-bearing potential or males with female partners who are pregnant or planning to become pregnant

• Infection with other HCV genotype or multiple HCV genotypes

• Poorly controlled diabetes

• Hemoglobinopathy or known retinal disease

• History of sarcoidosis or invasive malignancy

• Untreated or significant psychiatric illness

• Co-infection with hepatitis B virus or human immunodeficiency virus

• Chronic use of systemic immunosuppressive agents

• Autoimmune disorders

• Severe COPD

• History of significant cardiac disease

• Known cirrhosis

• Non-HCV chronic liver disease

• Transplantation

• Suspicion of hepatocellular carcinoma

• Bilirubin above the normal range or Gilbert's syndrome

• Decompensated liver disease

• Clinically significant illness

• GI disease that could interfere with absorption

• Acute porphyria

• Current excessive alcohol ingestion, averaging > 3 drinks/day for females and > 4 drinks/day for males or current binge drinking

• Positive urine drug screen

• History of difficult blood collection

• Significant recent blood loss

• Prohibited medications, including H2 antagonists, investigational agents

• Restricted fruits, fruit juices

• Hypersensitivity

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HCV Infection
• Hepatitis C
• Infection
• Virus Diseases

Intervention

Drug:
• GS-9256
75 mg BID x 28 days
• GS-9190
40 mg BID x 28 days
• Ribavirin
1000-1200 mg/day given BID
• Peginterferon alfa-2a
180 ug q week

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Gilead Sciences

Countries where clinical trial is conducted

Belgium,  France,  Germany,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of subjects achieving rapid virologic response (RVR)		Day 28	No
Primary	AEs, physical examination and clinical laboratory test findings, vital signs, ECGs		Throughout first six weeks of study	Yes
Secondary	Plasma pharmacokinetics		Throughout Day 28	No
Secondary	Viral resistance		Throughout study	No